KRN125 for Mobilization of Hematopoietic Stem Cells
Status:
Completed
Trial end date:
2020-08-28
Target enrollment:
Participant gender:
Summary
Data collection to evaluate safety and effect of hematopoietic stem cell mobilization into
the peripheral blood after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy
adults.